Dyax Corp. (NASDAQ:DYAX)
will host a webcast and conference call, including an open question and
answer session, Wednesday, February 13, 2013. During the call,
management will discuss the Company’s financial results for the fourth
quarter and the year ended December 31, 2012 and progress regarding its
key value drivers - the KALBITOR® (ecallantide) business and
angioedema portfolio, as well as the Licensing and Funded Research
Wednesday, February 13, 2013
5:00 p.m. ET
Domestic callers, dial 877-674-2415; reference the Dyax
International callers, dial 708-290-1364
No passcode required.
Go to the Investor Relations section of the Dyax website (www.dyax.com)
and follow instructions for accessing the live webcast.
Participants may register in advance.
A replay of the conference call will be available through February 20,
2013 and may be accessed by dialing 855-859-2056.International
callers should dial 404-537-3406. The replay passcode for all
callers is 89679769. The webcast will be archived on the Dyax
website for an indefinite period of time.
Dyax is a fully integrated biopharmaceutical company focused on the
discovery, development and commercialization of novel biotherapeutics
for unmet medical needs. The Company’s key value drivers are the KALBITOR®
(ecallantide) business and the angioedema portfolio, as well as the
Licensing and Funded Research Program (LFRP).
Dyax developed KALBITOR on its own and, since February 2010, the Company
has been selling it in the United States for the treatment of acute
attacks of hereditary angioedema (HAE) in patients 16 years of age and
older. Outside the United States, the Company has established
partnerships to obtain regulatory approval for and commercialization of
KALBITOR in certain markets and is evaluating opportunities in others.
The Company is currently developing products to expand its angioedema
portfolio, including diagnostic strategies to identify plasma kallikrein
(bradykinin) mediated (PKM) angioedema and a therapeutic candidate,
DX-2930, for the prophylactic treatment of, HAE and other PKM
KALBITOR and DX-2930 were identified using Dyax’s patented phage display
technology, which rapidly selects compounds that bind with high affinity
and specificity to therapeutic targets. Dyax leverages this technology
broadly through the LFRP. This program has provided the Company a
portfolio of product candidates being developed by its licensees, which
currently includes 12 royalty and/or milestone bearing product
candidates in various stages of clinical development, including three in
Phase 3 trials.
Dyax is headquartered in Burlington, Massachusetts. For additional
information about Dyax, please visit www.dyax.com.
Dyax Corp. Jennifer Robinson, 617-250-5741 Associate Director,
Investor Relations and Corporate Communications firstname.lastname@example.org